2019 Q1 Form 10-K Financial Statement
#000156459019006879 Filed on March 08, 2019
Income Statement
| Concept | 2019 Q1 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| Revenue | $0.00 | $320.0K | $111.0K |
| YoY Change | -100.0% | 357.14% | 0.91% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $3.690M | $2.590M | $2.650M |
| YoY Change | 26.8% | 18.81% | 16.74% |
| % of Gross Profit | |||
| Research & Development | $12.03M | $3.560M | $3.401M |
| YoY Change | 218.93% | 14.47% | 23.58% |
| % of Gross Profit | |||
| Depreciation & Amortization | $45.00K | $100.0K | $100.0K |
| YoY Change | 36.36% | 0.0% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $15.71M | $6.150M | $3.401M |
| YoY Change | 135.06% | 16.26% | -32.3% |
| Operating Profit | -$15.71M | -$5.944M | |
| YoY Change | 135.27% | 20.94% | |
| Interest Expense | $631.0K | $80.00K | $53.00K |
| YoY Change | 121.4% | 100.0% | -33.75% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $0.00 | $67.00K | |
| YoY Change | -100.0% | 318.75% | |
| Pretax Income | -$15.08M | -$5.750M | -$5.880M |
| YoY Change | 199.21% | 53.33% | 21.74% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$15.08M | -$5.750M | -$5.880M |
| YoY Change | 199.13% | 53.33% | 21.66% |
| Net Earnings / Revenue | -1796.88% | -5297.3% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$1.261M | -$1.261M | -$1.515M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 11.97M | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2019 Q1 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $105.3M | $32.40M | $32.40M |
| YoY Change | -26.62% | 89.47% | 35.0% |
| Cash & Equivalents | $25.07M | $14.47M | $32.39M |
| Short-Term Investments | $80.30M | $18.00M | $0.00 |
| Other Short-Term Assets | $3.800M | $6.600M | $6.800M |
| YoY Change | 100.0% | -67.8% | -78.68% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $0.00 | $100.0K | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $109.0M | $39.10M | $39.30M |
| YoY Change | -25.03% | 4.21% | -30.18% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.700M | $276.0K | $358.0K |
| YoY Change | 800.0% | -37.84% | -55.42% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $200.0K | $128.0K | $0.00 |
| YoY Change | 100.0% | 28.0% | -100.0% |
| Total Long-Term Assets | $2.900M | $413.0K | $330.0K |
| YoY Change | 480.0% | -27.42% | -64.44% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $109.0M | $39.10M | $39.30M |
| Total Long-Term Assets | $2.900M | $413.0K | $330.0K |
| Total Assets | $111.9M | $39.51M | $39.63M |
| YoY Change | -23.3% | 3.74% | -30.74% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $300.0K | $747.0K | $501.0K |
| YoY Change | -78.57% | -10.75% | -39.35% |
| Accrued Expenses | $4.100M | $2.700M | $2.100M |
| YoY Change | 173.33% | 92.86% | 90.91% |
| Deferred Revenue | $212.0K | ||
| YoY Change | |||
| Short-Term Debt | $0.00 | $5.100M | $5.800M |
| YoY Change | -73.71% | -80.86% | |
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $4.400M | $8.739M | $9.284M |
| YoY Change | 51.72% | -60.21% | -72.4% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $1.700M | $0.00 | $0.00 |
| YoY Change | 1600.0% | -100.0% | -100.0% |
| Total Long-Term Liabilities | $1.700M | $0.00 | $0.00 |
| YoY Change | 1600.0% | -100.0% | -100.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $4.400M | $8.739M | $9.284M |
| Total Long-Term Liabilities | $1.700M | $0.00 | $0.00 |
| Total Liabilities | $6.100M | $8.739M | $9.284M |
| YoY Change | 100.99% | -60.31% | -72.48% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$173.5M | -$161.9M | |
| YoY Change | 17.24% | 16.12% | |
| Common Stock | $6.000K | $4.000K | |
| YoY Change | 500.0% | -66.67% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $105.8M | $30.77M | $30.35M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $111.9M | $39.51M | $39.63M |
| YoY Change | -23.3% | 3.74% | -30.74% |
Cashflow Statement
| Concept | 2019 Q1 | 2017 Q4 | 2017 Q2 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$15.08M | -$5.750M | -$5.880M |
| YoY Change | 199.13% | 53.33% | 21.66% |
| Depreciation, Depletion And Amortization | $45.00K | $100.0K | $100.0K |
| YoY Change | 36.36% | 0.0% | 0.0% |
| Cash From Operating Activities | -$14.96M | -$6.300M | -$4.400M |
| YoY Change | 192.89% | 26.0% | 18.92% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $15.00K | $0.00 | $0.00 |
| YoY Change | -92.42% | -100.0% | -100.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $8.700M | -$1.500M | $0.00 |
| YoY Change | 770.0% | -125.0% | -100.0% |
| Cash From Investing Activities | $8.663M | -$1.500M | $0.00 |
| YoY Change | 978.83% | -125.86% | -100.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $9.700M | $18.60M | |
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 106.0K | 11.00M | 15.40M |
| YoY Change | -99.9% | 7600.0% | |
| NET CHANGE | |||
| Cash From Operating Activities | -14.96M | -6.300M | -4.400M |
| Cash From Investing Activities | 8.663M | -1.500M | 0.000 |
| Cash From Financing Activities | 106.0K | 11.00M | 15.40M |
| Net Change In Cash | -6.189M | 3.200M | 11.00M |
| YoY Change | -105.79% | 300.0% | -219.57% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$14.96M | -$6.300M | -$4.400M |
| Capital Expenditures | $15.00K | $0.00 | $0.00 |
| Free Cash Flow | -$14.97M | -$6.300M | -$4.400M |
| YoY Change | 182.24% | 31.25% | 25.71% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y11M4D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y2M1D | |
| CY2016Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
29858000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-71321000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-7000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-90000 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1287000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19940000 | |
| CY2017 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
14300000 | |
| CY2017 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
25472000 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14472000 | |
| CY2018Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
31213000 | |
| CY2018Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
88914000 | |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
17971000 | |
| CY2018Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
50000 | |
| CY2017Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
5333000 | |
| CY2018Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3814000 | |
| CY2018Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
543000 | |
| CY2017Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
128000 | |
| CY2017Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
212000 | |
| CY2018Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
4801000 | |
| CY2018Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
174000 | |
| CY2018Q4 | us-gaap |
Liabilities
Liabilities
|
4975000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
8739000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2018Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
12000 | |
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
6000 | |
| CY2018Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
323279000 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
204262000 | |
| CY2018Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-4000 | |
| CY2018Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-203342000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-173494000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
119945000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
30774000 | |
| CY2018Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
124920000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
39513000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
3680 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
3680 | |
| CY2018Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
11954528 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6081230 | |
| CY2018Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
11954528 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6081230 | |
| CY2018 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
6000 | |
| CY2017 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
1018000 | |
| CY2018 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
cbio:ContractMember | |
| CY2017 | us-gaap |
Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
|
cbio:ContractMember | |
| CY2017 | cbio |
Stock Issued During Period Value Convertible Preferred Stock Common Stock And Warrants For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueConvertiblePreferredStockCommonStockAndWarrantsForFollowOnOfferingNetOfIssuanceCosts
|
18563000 | |
| CY2017 | cbio |
Stock Issued During Period Value Common Stock For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockForFollowOnOfferingNetOfIssuanceCosts
|
9684000 | |
| CY2017 | cbio |
Stock Issued During Period Value Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants
|
1817000 | |
| CY2017Q4 | us-gaap |
Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
|
207000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
|
30981000 | |
| CY2018 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2606000 | |
| CY2018 | cbio |
Stock Issued During Period Value Common Stock For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockForFollowOnOfferingNetOfIssuanceCosts
|
106762000 | |
| CY2018 | cbio |
Stock Issued During Period Value Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants
|
9545000 | |
| CY2018 | cbio |
Stock Issued During Period From Stock Grants And Stock Options Exercised Value
StockIssuedDuringPeriodFromStockGrantsAndStockOptionsExercisedValue
|
107000 | |
| CY2018 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
3000 | |
| CY2018 | cbio |
Stock Grants Elected To Receive In Lieu Of Cash Compensation For Board Of Director Fees
StockGrantsElectedToReceiveInLieuOfCashCompensationForBoardOfDirectorFees
|
6790 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
351000 | |
| CY2018 | us-gaap |
Profit Loss
ProfitLoss
|
-30055000 | |
| CY2017 | us-gaap |
Profit Loss
ProfitLoss
|
-21561000 | |
| CY2018 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2606000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
863000 | |
| CY2018 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
149000 | |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
173000 | |
| CY2018 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-116000 | |
| CY2017 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-18000 | |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2895000 | |
| CY2017 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
128000 | |
| CY2018 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11458000 | |
| CY2017 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-10053000 | |
| CY2018 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
500000 | |
| CY2018 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
850000 | |
| CY2018 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-6000 | |
| CY2017 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-118000 | |
| CY2018 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
-182000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
40000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-28553000 | |
| CY2018 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
127967000 | |
| CY2018 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
198912000 | |
| CY2018 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
376000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
23000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-11195000 | |
| CY2018 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
5082000 | |
| CY2017 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
14318000 | |
| CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5336000 | |
| CY2017 | cbio |
Proceeds From Issuance Of Preferred Stock Common Stock And Warrants For Follow On Offering Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockCommonStockAndWarrantsForFollowOnOfferingNetOfIssuanceCosts
|
18563000 | |
| CY2018 | cbio |
Proceeds From Exercise Of Stock Options And Issuance Of Stock Grants
ProceedsFromExerciseOfStockOptionsAndIssuanceOfStockGrants
|
107000 | |
| CY2018 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
9545000 | |
| CY2017 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1817000 | |
| CY2018 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
111332000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
21082000 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
19805000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
31263000 | |
| CY2017 | cbio |
Noncash Or Part Noncash Deemed Dividend For Convertible Preferred Stock Beneficial Conversion Feature
NoncashOrPartNoncashDeemedDividendForConvertiblePreferredStockBeneficialConversionFeature
|
3951000 | |
| CY2018 | cbio |
Noncash Impact On Adoption Of New Accounting Principle
NoncashImpactOnAdoptionOfNewAccountingPrinciple
|
207000 | |
| CY2018 | us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
3000 | |
| CY2018 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
4000 | |
| CY2017 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
1000 | |
| CY2018 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-top:8pt;margin-bottom:0pt;font-size:10pt;font-weight:bold;">1.</p></td> <td valign="top"> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED"></a><a name="NOTES_TO_CONSOLIDATED"></a>Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the “Company” or “Catalyst”) is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment. Prior to August 20, 2015, the name of the Company was Targacept, Inc. (“Targacept”). On August 20, 2015, Targacept completed its business combination with Catalyst (the “Merger”).</p> | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
6000 | |
| CY2018 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p> | |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
37638000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
119057000 | |
| CY2018Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
2000 | |
| CY2018 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2018 | us-gaap |
Lease Practical Expedients Package
LeasePracticalExpedientsPackage
|
true | |
| CY2017Q4 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
| CY2018 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
50000 | |
| CY2017 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
100000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
158.81 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
37638000 | |
| CY2018 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2018Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
671000 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2299000 | |
| CY2018Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
285000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2023000 | |
| CY2018 | us-gaap |
Depreciation
Depreciation
|
100000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2018 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
400000 | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
800000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
571000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
587000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
605000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
617000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
209000 | |
| CY2018Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2589000 | |
| CY2013 | cbio |
License Fees Payable
LicenseFeesPayable
|
100000 | |
| CY2018Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
0 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
742000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
61249 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
821741 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
612050 | |
| CY2018 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
12716 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
43315 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
15783 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1361977 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
414584 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1361977 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
1295144 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
128.25 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
4.56 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
165.63 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.69 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
13.13 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.17 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
7.76 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
12.04 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
17.98 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
12.04 | |
| CY2018 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y8M15D | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
6376000 | |
| CY2018 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
213000 | |
| CY2018Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2294000 | |
| CY2018 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2580000 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
863000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.2100 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0003 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0000 | |
| CY2018 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0068 | |
| CY2017 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0060 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.0076 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.0164 | |
| CY2018 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
0.2016 | |
| CY2017 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
-0.5408 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
23559000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11519000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3772000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3545000 | |
| CY2018Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
3000 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.3933 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.5290 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.0000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.3389 | |
| CY2018 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
-0.0194 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.0003 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
751000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1112000 | |
| CY2018 | cbio |
Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Forfeited
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightForfeited
|
5.50 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
155.73 | |
| CY2018Q2 | cbio |
Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
|
4250 | |
| CY2017Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9700000 | |
| CY2018Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
106800000 | |
| CY2018 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1372171 | |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3346332 | |
| CY2017Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
89000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
28085000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
16265000 | |
| CY2018 | cbio |
Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
|
6100000 | |
| CY2018Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1573000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1475000 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1539000 | |
| CY2017 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
-126000 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
62000 | |
| CY2018 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
13000 | |
| CY2018 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
85000 | |
| CY2018Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2017Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2018Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2017Q4 | us-gaap |
Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
|
0 | |
| CY2018 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2229000 | |
| CY2017 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
215000 | |
| CY2018 | us-gaap |
Investment Income Dividend
InvestmentIncomeDividend
|
4000 | |
| CY2017 | us-gaap |
Investment Income Dividend
InvestmentIncomeDividend
|
50000 | |
| CY2018 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1650000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1000 | |
| CY2018 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-116000 | |
| CY2017 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
-3000 | |
| CY2018 | cbio |
Milestone Payment Received
MilestonePaymentReceived
|
1500000 | |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2070000 | |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.50 | |
| CY2017Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
18600000 | |
| CY2017Q2 | us-gaap |
Share Price
SharePrice
|
5.28 | |
| CY2017Q2 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
5000000 | |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
12039 | |
| CY2017 | cbio |
Class Of Warrant Or Right Warrants Issued During Period
ClassOfWarrantOrRightWarrantsIssuedDuringPeriod
|
2070000 | |
| CY2017 | cbio |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
330331 | |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1751708 | |
| CY2018 | cbio |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
1735419 | |
| CY2018 | cbio |
Class Of Warrant Or Right Forfeited During Period
ClassOfWarrantOrRightForfeitedDuringPeriod
|
6095 | |
| CY2018Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
10194 | |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
145.11 | |
| CY2017 | cbio |
Class Of Warrant Or Right Exercise Price Per Warrant Or Right Issued
ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued
|
5.50 | |
| CY2017 | cbio |
Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Exercised
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised
|
5.50 | |
| CY2018 | cbio |
Class Of Warrant Or Right Weighted Average Exercise Price Per Warrants Or Right Exercised
ClassOfWarrantOrRightWeightedAverageExercisePricePerWarrantsOrRightExercised
|
5.50 |
